Overview

Corporate Presentation

Corporate Presentation - August 2024

Download Presentation

Email Alerts

IR Contacts

Get in touch with our IR team

Latest Press Releases

Investor Alerts

Sep 4, 2024

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024

Professor Jacky Smith will present on the correlation between the change in objective cough count and improvement in patient-reported outcomes with nalbuphine ER in IPF patients NEW HAVEN, Conn.,...

Aug 28, 2024

Trevi Therapeutics to Participate in September Investor and Medical Conferences

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in...

Aug 8, 2024

Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance

Topline results expected in the fourth quarter of 2024 in the Phase 2a RIVER trial in refractory chronic cough (RCC) Sample size re-estimation milestone is expected in the fourth quarter of 2024...

View All Press Releases

Events

2024 Cantor Global Healthcare Conference

Thursday, September 19, 2024

8:35am - 9:05am CDT

Corporate Presentation: September 19, 8:35 a.m. – 9:05 a.m. CET, Track 6

Add to Calendar

Set Email Reminder

View All Events

We are developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis. Haduvio has a unique mechanism of action that targets cough centrally and peripherally and has the potential for a synergistic anti-tussive effect to treat chronic cough.

Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of chronic cough patients who currently have few treatment options.

Explore Our Pipeline